IN

Integrum ABFNSE Integrum Stock Report

Last reporting period 31 Oct, 2023

Updated 21 Oct, 2024

Last price

Market cap $B

0.01

Micro

Exchange

FNSE - First North Sweden

INTEG B.ST Stock Analysis

IN

Uncovered

Integrum AB is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

5/100

Low score

Market cap $B

0.01

Dividend yield

Shares outstanding

17.58 B

Integrum AB engages in the manufacturing of medical devices. The company is headquartered in Moelndal, Vastra Gotalands and currently employs 31 full-time employees. The company went IPO on 2017-05-15. The company provides systems for bone-anchored prostheses for individuals with amputations. The Company’s solutions comprise OPRA Implant System, neural prosthetics, phantom limb pain treatment and prosthetic components. The OPRA implant system is based on osseointegration, enabling the direct connection of an artificial limb to the skeleton. The neural prosthetics technology implies ability to directly connect bionic prostheses to the patient’s bone, nerves, and muscles. A method for limb pain treatment implies motor execution of the phantom limb as a treatment, which is aided by machine learning, augmented and virtual reality. The firm provides a variety of prosthetic components required to connect the OPRA Implant System to external prostheses.

View Section: Eyestock Rating